-
1
-
-
0028948839
-
A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
-
Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
-
(1995)
Pharm Res
, vol.12
, pp. 413-420
-
-
Amidon, G.L.1
Lennernas, H.2
Shah, V.P.3
Crison, J.R.4
-
2
-
-
65549101635
-
The Science of USP 1 and 2 dissolution: Present challenges and future relevance
-
Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S. 2009. The Science of USP 1 and 2 dissolution: Present challenges and future relevance. Pharm Res 26:1289-1302.
-
(2009)
Pharm Res
, vol.26
, pp. 1289-1302
-
-
Gray, V.1
Kelly, G.2
Xia, M.3
Butler, C.4
Thomas, S.5
Mayock, S.6
-
3
-
-
77955947927
-
The use of biorelevant dissolution media to forecast the in vivo performance of a drug
-
Klein S. 2010. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J 12:397-406.
-
(2010)
AAPS J
, vol.12
, pp. 397-406
-
-
Klein, S.1
-
4
-
-
85030489424
-
-
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidances for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
-
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2000. Guidances for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
-
(2000)
-
-
-
5
-
-
80054946642
-
-
European Medicines Agency (EMA). Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence.
-
European Medicines Agency (EMA). 2010. Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence.
-
(2010)
-
-
-
6
-
-
77955248335
-
The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation
-
Tsume Y, Amidon GL. 2010. The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm 7:1235-1243.
-
(2010)
Mol Pharm
, vol.7
, pp. 1235-1243
-
-
Tsume, Y.1
Amidon, G.L.2
-
7
-
-
0032927254
-
Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications
-
Fleisher D, Li C, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254.
-
(1999)
Clin Pharmacokinet
, vol.36
, pp. 233-254
-
-
Fleisher, D.1
Li, C.2
Zhou, Y.3
Pao, L.H.4
Karim, A.5
-
8
-
-
65549103408
-
Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects
-
Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. 2009. Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects. AAPS J 11:45-53.
-
(2009)
AAPS J
, vol.11
, pp. 45-53
-
-
Parrott, N.1
Lukacova, V.2
Fraczkiewicz, G.3
Bolger, M.B.4
-
9
-
-
28444451169
-
A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study
-
Kuentz M, Nick S, Parrott N, Röthlisberger D. 2006. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 27:91-99.
-
(2006)
Eur J Pharm Sci
, vol.27
, pp. 91-99
-
-
Kuentz, M.1
Nick, S.2
Parrott, N.3
Röthlisberger, D.4
-
10
-
-
43349105478
-
Rationale for ibuprofen co-administration with antacids: Potential interaction mechanisms affecting drug absorption
-
Parojčić J, Corrigan OI. 2008. Rationale for ibuprofen co-administration with antacids: Potential interaction mechanisms affecting drug absorption. Eur J Pharm Biopharm 69:640-647.
-
(2008)
Eur J Pharm Biopharm
, vol.69
, pp. 640-647
-
-
Parojčić, J.1
Corrigan, O.I.2
-
11
-
-
0024447995
-
Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers
-
Polk RE, Healy DP, Sahai J, Drwal L, Racht E. 1989. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 33:1841-1844.
-
(1989)
Antimicrob Agents Chemother
, vol.33
, pp. 1841-1844
-
-
Polk, R.E.1
Healy, D.P.2
Sahai, J.3
Drwal, L.4
Racht, E.5
-
12
-
-
0025054283
-
Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate
-
Brouwers JR, Van der Kam HJ, Sijtsma J, Proost JH. 1990. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. Pharm Weekbl Sci 12:182-183.
-
(1990)
Pharm Weekbl Sci
, vol.12
, pp. 182-183
-
-
Brouwers, J.R.1
Van der Kam, H.J.2
Sijtsma, J.3
Proost, J.H.4
-
13
-
-
0025978806
-
Clinical and chemical interactions between iron preparations and ciprofloxacin
-
Campbell
-
Kara M, Hasinoff BB, McKay WD, Campbell 1991. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 31:257-261.
-
(1991)
Br J Clin Pharmacol
, vol.31
, pp. 257-261
-
-
Kara, M.1
Hasinoff, B.B.2
McKay, W.D.3
-
14
-
-
0028235252
-
The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin
-
Lehto P, Kivisto TK, Neuvonen JP. 1994. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 37:82-85.
-
(1994)
Br J Clin Pharmacol
, vol.37
, pp. 82-85
-
-
Lehto, P.1
Kivisto, T.K.2
Neuvonen, J.P.3
-
15
-
-
0029923883
-
Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption
-
Pazzucconi E, Barbi S, Baldassarre D, Colombo N, Dorigotti F, Sirtori CR. 1996. Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. Clin Pharmacol Ther 59:418-422.
-
(1996)
Clin Pharmacol Ther
, vol.59
, pp. 418-422
-
-
Pazzucconi, E.1
Barbi, S.2
Baldassarre, D.3
Colombo, N.4
Dorigotti, F.5
Sirtori, C.R.6
-
16
-
-
0025972964
-
Iron supplements: A common cause of drug interactions
-
Campbell RCN, Hasinoff BB. 1991. Iron supplements: A common cause of drug interactions. Br J Clin Pharmacol 31:251-255.
-
(1991)
Br J Clin Pharmacol
, vol.31
, pp. 251-255
-
-
Campbell, R.C.N.1
Hasinoff, B.B.2
-
18
-
-
0028344283
-
A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polyvalent cations
-
Sanchez BM, Cabarga MM, Navarro AS, Hurle AD. 1994. A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polyvalent cations. Int J Pharm 106:229-235.
-
(1994)
Int J Pharm
, vol.106
, pp. 229-235
-
-
Sanchez, B.M.1
Cabarga, M.M.2
Navarro, A.S.3
Hurle, A.D.4
-
20
-
-
77954860340
-
Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier
-
Žakelj S, Berginc K, Ursic D, Veber M, Kristl A. 2010. Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier. J Pharm Biomed Anal 53:655-659.
-
(2010)
J Pharm Biomed Anal
, vol.53
, pp. 655-659
-
-
Žakelj, S.1
Berginc, K.2
Ursic, D.3
Veber, M.4
Kristl, A.5
-
21
-
-
28444462195
-
Interactions between ciprofloxacin and antacids-dissolution and adsorption studies
-
Arayne MS, Sultana N, Hussain F. 2005. Interactions between ciprofloxacin and antacids-dissolution and adsorption studies. Drug Metabol Drug Interact 21(2):117-129.
-
(2005)
Drug Metabol Drug Interact
, vol.21
, Issue.2
, pp. 117-129
-
-
Arayne, M.S.1
Sultana, N.2
Hussain, F.3
-
22
-
-
34247142812
-
Influence of metal cations on the solubility of fluoroquinolones
-
Žakelj S, Berginc K, Ursic D, Kristl A. 2007. Influence of metal cations on the solubility of fluoroquinolones. Pharmazie 62:318-320.
-
(2007)
Pharmazie
, vol.62
, pp. 318-320
-
-
Žakelj, S.1
Berginc, K.2
Ursic, D.3
Kristl, A.4
-
23
-
-
0036783919
-
The interactions of metal ions with quinolone antibacterial agents
-
Turel I. 2002. The interactions of metal ions with quinolone antibacterial agents. Coord Chem Rev 232:22-47.
-
(2002)
Coord Chem Rev
, vol.232
, pp. 22-47
-
-
Turel, I.1
-
24
-
-
67649336602
-
Analysis of the factors that significantly influence the stability of fluoroquinolone-metal complexes
-
Urbaniak B, Kokot Z. 2009. Analysis of the factors that significantly influence the stability of fluoroquinolone-metal complexes. Anal Chim Acta 647:54-59.
-
(2009)
Anal Chim Acta
, vol.647
, pp. 54-59
-
-
Urbaniak, B.1
Kokot, Z.2
-
25
-
-
40949123409
-
Iron (III) complexes: Preparation, characterization, antibacterial activity and DNA-binding
-
Pansuriya PB, Patel MN. 2008. Iron (III) complexes: Preparation, characterization, antibacterial activity and DNA-binding. J Enzyme Inhib Med Chem 23:230-239.
-
(2008)
J Enzyme Inhib Med Chem
, vol.23
, pp. 230-239
-
-
Pansuriya, P.B.1
Patel, M.N.2
-
26
-
-
0037454602
-
Iron (II) and iron (III) perchlorate complexes of ciprofloxacin and norfloxacin
-
Al-Mustafa J, Tashtoush B. 2003. Iron (II) and iron (III) perchlorate complexes of ciprofloxacin and norfloxacin. J Coord Chem 56:113-124.
-
(2003)
J Coord Chem
, vol.56
, pp. 113-124
-
-
Al-Mustafa, J.1
Tashtoush, B.2
-
27
-
-
78650060225
-
Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride
-
Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2011. Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride. J Pharm Sci 100:22-33.
-
(2011)
J Pharm Sci
, vol.100
, pp. 22-33
-
-
Olivera, M.E.1
Manzo, R.H.2
Junginger, H.E.3
Midha, K.K.4
Shah, V.P.5
Stavchansky, S.6
Dressman, J.B.7
Barends, D.M.8
-
28
-
-
0023794347
-
Pharmacokinetics of intravenous ciprofloxacin at three different doses
-
Ljungberg B, Nilsson-Ehle I. 1988. Pharmacokinetics of intravenous ciprofloxacin at three different doses. J Antimicrob Chemother 22:715-720.
-
(1988)
J Antimicrob Chemother
, vol.22
, pp. 715-720
-
-
Ljungberg, B.1
Nilsson-Ehle, I.2
-
29
-
-
0035478779
-
Predicting the impact of physiological and biochemical processes on oral drug bioavailability
-
Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50:41-67.
-
(2001)
Adv Drug Deliv Rev
, vol.50
, pp. 41-67
-
-
Agoram, B.1
Woltosz, W.S.2
Bolger, M.B.3
-
30
-
-
3242728351
-
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification
-
Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennerna H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
-
(2004)
Mol Pharm
, vol.1
, pp. 85-96
-
-
Kasim, N.A.1
Whitehouse, M.2
Ramachandran, C.3
Bermejo, M.4
Lennerna, H.5
Hussain, A.S.6
Junginger, H.E.7
Stavchansky, S.A.8
Midha, K.K.9
Shah, V.P.10
Amidon, G.L.11
-
31
-
-
80054956785
-
-
pION INC. Molecule of the month-ciprofloxacin HCl.
-
pION INC. 2003. Molecule of the month-ciprofloxacin HCl.
-
(2003)
-
-
-
32
-
-
0025300849
-
Extravascular penetration of ciprofloxacin
-
Bergan T. 1990. Extravascular penetration of ciprofloxacin. Diagn Microbiol Infect Dis 13:103-104.
-
(1990)
Diagn Microbiol Infect Dis
, vol.13
, pp. 103-104
-
-
Bergan, T.1
-
33
-
-
0004144140
-
-
Martindale. 34th edition. London, UK: Royal Pharmaceutical Society.
-
Martindale. 2004. The Extra Pharmacopoeia. 34th edition. London, UK: Royal Pharmaceutical Society.
-
(2004)
The Extra Pharmacopoeia
-
-
-
34
-
-
0021918956
-
Pharmacokinetics of ciprofloxacin after oral and parenteral administration
-
Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P. 1985. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27:375-379.
-
(1985)
Antimicrob Agents Chemother
, vol.27
, pp. 375-379
-
-
Hoffken, G.1
Lode, H.2
Prinzing, C.3
Borner, K.4
Koeppe, P.5
-
36
-
-
0022576892
-
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration
-
Borner K, Höffken G, Lode H, Koeppe P, Prinzing C, Glatzel P, Wiley R, Olschewski P, Sievers B, Reinitz D. 1986. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol 5:179-186.
-
(1986)
Eur J Clin Microbiol
, vol.5
, pp. 179-186
-
-
Borner, K.1
Höffken, G.2
Lode, H.3
Koeppe, P.4
Prinzing, C.5
Glatzel, P.6
Wiley, R.7
Olschewski, P.8
Sievers, B.9
Reinitz, D.10
-
37
-
-
0022531964
-
Absolute oral bioavailability of ciprofloxacin
-
Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. 1986. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 30:444-446.
-
(1986)
Antimicrob Agents Chemother
, vol.30
, pp. 444-446
-
-
Drusano, G.L.1
Standiford, H.C.2
Plaisance, K.3
Forrest, A.4
Leslie, J.5
Caldwell, J.6
-
38
-
-
0023202748
-
Effect of dose size on bioavailability of ciprofloxacin
-
Plaisance KI, Drusano GL, Forrest A, Bustamante CI, Standiford HC. 1987. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 31:956-958.
-
(1987)
Antimicrob Agents Chemother
, vol.31
, pp. 956-958
-
-
Plaisance, K.I.1
Drusano, G.L.2
Forrest, A.3
Bustamante, C.I.4
Standiford, H.C.5
-
39
-
-
0026692148
-
Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses
-
Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 36:993-996.
-
(1992)
Antimicrob Agents Chemother
, vol.36
, pp. 993-996
-
-
Lettieri, J.T.1
Rogge, M.C.2
Kaiser, L.3
Echols, R.M.4
Heller, A.H.5
-
40
-
-
0025309060
-
Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule
-
Harder S, Fuhr U, Beermann D, Staib AH. 1990. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule. Br J Clin Pharmacol 30:35-39.
-
(1990)
Br J Clin Pharmacol
, vol.30
, pp. 35-39
-
-
Harder, S.1
Fuhr, U.2
Beermann, D.3
Staib, A.H.4
-
41
-
-
27744515754
-
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging
-
Schiller C, Frohlich CP, Giessmann T, Siegmund W, Monnikes H, Hosten N, Weitschies W. 2005. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 22:971-979.
-
(2005)
Aliment Pharmacol Ther
, vol.22
, pp. 971-979
-
-
Schiller, C.1
Frohlich, C.P.2
Giessmann, T.3
Siegmund, W.4
Monnikes, H.5
Hosten, N.6
Weitschies, W.7
-
42
-
-
75149175153
-
Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome
-
Marciani L, Cox EF, Hoad CL, Pritchard S, Totman JJ, Foley S, Mistry A, Evans S, Gowland PA, Spiller RC. 2010. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 138:469-490.
-
(2010)
Gastroenterology
, vol.138
, pp. 469-490
-
-
Marciani, L.1
Cox, E.F.2
Hoad, C.L.3
Pritchard, S.4
Totman, J.J.5
Foley, S.6
Mistry, A.7
Evans, S.8
Gowland, P.A.9
Spiller, R.C.10
-
43
-
-
68249133855
-
Role of physiological intestinal water in oral absorption
-
Sutton CS. 2009. Role of physiological intestinal water in oral absorption. AAPS J 11:277-285.
-
(2009)
AAPS J
, vol.11
, pp. 277-285
-
-
Sutton, C.S.1
-
44
-
-
77957729822
-
Quantitative analysis of the effect of supersaturation on in vivo drug absorption
-
Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S. 2010. Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm 7:1431-1440.
-
(2010)
Mol Pharm
, vol.7
, pp. 1431-1440
-
-
Takano, R.1
Takata, N.2
Saito, R.3
Furumoto, K.4
Higo, S.5
Hayashi, Y.6
Machida, M.7
Aso, Y.8
Yamashita, S.9
-
45
-
-
77957016539
-
Adsorption and intercalation of ciprofloxacin on montmorillonite
-
Wu Q, Li Z, Hong H, Yin K, Tie L. 2010. Adsorption and intercalation of ciprofloxacin on montmorillonite. Appl Clay Sci 50:204-211.
-
(2010)
Appl Clay Sci
, vol.50
, pp. 204-211
-
-
Wu, Q.1
Li, Z.2
Hong, H.3
Yin, K.4
Tie, L.5
-
46
-
-
0028578066
-
Synthesis, characterization and crystal structure of copper(II) complex with quinolone family member (Ciprofloxacin): Bis(1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate)copper(II) chloride hexahydrate
-
Turel I, Leban I, Bukovec N. 1994. Synthesis, characterization and crystal structure of copper(II) complex with quinolone family member (Ciprofloxacin): Bis(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate)copper(II) chloride hexahydrate. J Inorg Biochem 56:273-282.
-
(1994)
J Inorg Biochem
, vol.56
, pp. 273-282
-
-
Turel, I.1
Leban, I.2
Bukovec, N.3
|